News | May 19, 2026
Lupin debuts in Dow Jones best-in-class indices for ESG performance
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The celebrations began with the unveiling of the Biocon Anthem
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Subscribe To Our Newsletter & Stay Updated
